Among the HR‐positive patients, significant differences in age, N stage, histological subtype, tumor‐infiltrating lymphocytes (TILs), androgen receptor (AR) status, TOPIIa, and surgical modality were found between the HER2‐low and HER2‐0 BC patient groups (p < 0.05; Table 2). This evidence concerns the gene ERBB2 and breast cancer.